SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

DENVER, Oct. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Stanford Medicine is cleared to actively enroll subjects in the NEUTRALIZE-AKI pivotal trial. With the recent addition of two Department of Defense medical centers, 12 sites are now activated to enroll subjects in the trial with enrollment at 52.

Read more at globenewswire.com